公开(公告)号：US20240182557A1

公开(公告)日：2024-06-06

申请号：US18383310

申请日：2023-10-24

Applicant: Janssen Biotech, Inc.

Inventor： Jewel Johanns ,  Katherine Li ,  Colleen Marano ,  Richard Strauss ,  Hongyan Zhang ,  Christopher O'Brien ,  Omoniyi Adedokun ,  Kimberly Shields-Tuttle

IPC: C07K16/24 ,  A61K9/00 ,  A61K9/08 ,  A61K39/00 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26 ,  A61P1/04

CPC classification number: C07K16/244 ,  A61K9/0019 ,  A61K9/08 ,  A61K39/00 ,  A61K47/183 ,  A61K47/22 ,  A61K47/26 ,  A61P1/04 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/31 ,  C07K2317/565

Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.

公开(公告)号：US20240002494A1

公开(公告)日：2024-01-04

申请号：US18210885

申请日：2023-06-16

Applicant: Janssen Biotech, Inc.

Inventor： Jewel Johanns ,  Katherine Li ,  Colleen Marano ,  Richard Strauss ,  Hongyan Zhang ,  Christopher O'Brien ,  Omoniyi Adedokun ,  Kimberly Shields-Tuttle

IPC: C07K16/24 ,  A61P1/04

CPC classification number: C07K16/244 ,  A61P1/04 ,  A61K2039/545

Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.

公开(公告)号：US20230159633A1

公开(公告)日：2023-05-25

申请号：US17992369

申请日：2022-11-22

Applicant: Janssen Biotech, Inc.

Inventor： Matthew Germinaro ,  Kuan-hsiang Gary Huang ,  Hongyan Zhang

IPC: C07K16/24 ,  A61K45/06 ,  A61K39/395 ,  A61P1/04 ,  A61K31/519 ,  C07K16/28

CPC classification number: C07K16/244 ,  A61K45/06 ,  A61K39/3955 ,  A61P1/04 ,  A61K31/519 ,  C07K16/2887 ,  A61K2039/545

Abstract: A method of treating ulcerative colitis in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial dose and subsequent doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.

公开(公告)号：US10961307B2

公开(公告)日：2021-03-30

申请号：US16580509

申请日：2019-09-24

Applicant: Janssen Biotech, Inc.

Inventor： Jewel Johanns ,  Katherine Li ,  Colleen Marano ,  Richard Strauss ,  Hongyan Zhang ,  Christopher O'Brien ,  Omoniyi Adedokun ,  Kimberly Shields-Tuttle

IPC: A61K39/00 ,  C07K16/24 ,  A61K9/08 ,  A61K47/22 ,  A61K47/26 ,  A61K47/18 ,  A61P1/04 ,  A61K9/00

Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.

公开(公告)号：US20200095315A1

公开(公告)日：2020-03-26

申请号：US16580509

申请日：2019-09-24

Applicant: Janssen Biotech, Inc.

Inventor： Jewel Johans ,  Katherine Li ,  Colleen Marano ,  Richard Strauss ,  Hongyan Zhang ,  Christopher O'Brien ,  Omoniyi Adedokun ,  Kimberly Shields-Tuttle

IPC: C07K16/24 ,  A61K9/08 ,  A61K47/22 ,  A61K47/26 ,  A61K47/18 ,  A61K9/00 ,  A61P1/04

Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.

公开(公告)号：US20240294625A1

公开(公告)日：2024-09-05

申请号：US18401874

申请日：2024-01-02

Applicant: Janssen Biotech, Inc.

Inventor： Omoniyi Adedokun ,  Jewel Johanns ,  Katherine Li ,  Colleen Marano ,  Christopher O'Brien ,  Kimberly Shields-Tuttle ,  Richard Strauss ,  Hongyan Zhang

IPC: C07K16/24 ,  A61K9/00 ,  A61K39/00 ,  A61K39/395 ,  A61K47/18 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61P1/04

CPC classification number: C07K16/244 ,  A61K9/0019 ,  A61K39/3955 ,  A61K47/183 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61P1/04 ,  A61K2039/505 ,  C07K2317/565

Abstract: Described are methods and compositions for clinically proven safe and effective treatment of ulcerative colitis according to the product label described herein, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.

公开(公告)号：US20210171622A1

公开(公告)日：2021-06-10

申请号：US17174201

申请日：2021-02-11

Applicant: Janssen Biotech, Inc.

Inventor： Jewel Johanns ,  Katherine Li ,  Colleen Marano ,  Richard Strauss ,  Hongyan Zhang ,  Christopher O'Brien ,  Omoniyi Adedokun ,  Kimberly Shields-Tuttle

IPC: C07K16/24 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26 ,  A61K39/00 ,  A61P1/04 ,  A61K9/08 ,  A61K9/00

Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.

公开(公告)号：US20240199734A1

公开(公告)日：2024-06-20

申请号：US18517248

申请日：2023-11-22

Applicant: Janssen Biotech, Inc.

Inventor： Matthew Germinaro ,  Kuan-hsiang Gary Huang ,  Hongyan Zhang

IPC: C07K16/24 ,  A61K9/00 ,  A61K39/00 ,  A61P1/04

CPC classification number: C07K16/244 ,  A61K9/0019 ,  A61P1/04 ,  A61K39/00 ,  A61K2039/505 ,  C07K2317/21

Abstract: A method of treating ulcerative colitis in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial dose and subsequent doses in order for the patient to respond to the antibody and meet one or more of the clinical endpoints.

公开(公告)号：US20210253690A1

公开(公告)日：2021-08-19

申请号：US17175129

申请日：2021-02-12

Applicant: Janssen Biotech, Inc.

Inventor： Jewel Johanns ,  Katherine Li ,  Colleen Marano ,  Richard Strauss ,  Hongyan Zhang ,  Christopher O'Brien ,  Omoniyi Adedokun ,  Kimberly Shields-Tuttle

IPC: C07K16/24 ,  A61P1/04

Abstract: Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.

公开(公告)号：US20210115129A1

公开(公告)日：2021-04-22

申请号：US17072298

申请日：2020-10-16

Applicant: Janssen Biotech, Inc.

Inventor： Jewel Johanns ,  Katherine Li ,  Colleen Marano ,  Richard Strauss ,  Hongyan Zhang ,  Christopher O'Brien ,  Omoniyi Adedokun ,  Kimberly Shields-Tuttle

IPC: C07K16/24 ,  A61P1/04 ,  A61K9/00 ,  A61K47/22 ,  A61K47/26 ,  A61K47/20 ,  A61K47/18 ,  A61K39/395

Abstract: Described are methods and compositions for clinically proven safe and effective treatment of ulcerative colitis according to the product label described herein, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.